Jeffrey Santi, MD
Family Medicine · Moncks Corner, SCNPI 1326073412
Payments from drug & device makers
Across 161 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$350
- Novo Nordisk$344
- Novartis$315
- Pfizer$302
- GSK$187
- AstraZeneca$158
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,918100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 16 | $350 |
| Novo Nordisk | 21 | $344 |
| Novartis | 17 | $315 |
| Pfizer | 19 | $302 |
| GSK | 11 | $187 |
| AstraZeneca | 10 | $158 |
| Lilly USA, LLC | 9 | $145 |
| Boston Scientific | 3 | $136 |
| Dexcom, Inc. | 3 | $97 |
| AbbVie | 6 | $93 |
| Amgen | 5 | $92 |
| Astellas Pharma US Inc | 5 | $81 |
| Medtronic | 3 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $55 |
| Bayer | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Shire North American Group Inc | 3 | $47 |
| Corcept Therapeutics | 2 | $43 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Johnson & Johnson | 2 | $29 |
| Coloplast | 1 | $24 |
| Radius Health, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Inari Medical, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Edwards Lifesciences | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,918 in reported general payments places this provider in the 75th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 110 | $172,909 |
| JardianceEmpagliflozin | 128 | $118,756 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $104,878 |
| EliquisApixaban | 112 | $100,260 |
| TrulicityDulaglutide | 56 | $69,999 |
| FarxigaDapagliflozin Propanediol | 82 | $58,266 |
| JanuviaSitagliptin Phosphate | 52 | $43,108 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $41,516 |
| MounjaroTirzepatide | 41 | $39,601 |
| XareltoRivaroxaban | 49 | $35,492 |
| EntrestoSacubitril/Valsartan | 47 | $34,978 |
| MyrbetriqMirabegron | 34 | $25,842 |
| RexultiBrexpiprazole | 14 | $23,555 |
| LinzessLinaclotide | 15 | $23,214 |
| RybelsusSemaglutide | 14 | $19,797 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $344 | $192,706124 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $187 | $121,960116 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $145 | $109,60097 claims |
| PfizerEliquis | $302 | $100,260112 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $158 | $67,68295 claims |
| Johnson & JohnsonXarelto | $29 | $35,49249 claims |
| NovartisEntresto | $315 | $34,97847 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $25,84234 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $48 | $23,55514 claims |
| AbbVieLinzess | $93 | $23,21415 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $36 | $19,38125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Moncks Corner
- Jeremy AckermannMoncks Corner$7.6M
- Nathan AverillMoncks Corner$25K
- Cayce TangemanGoose Creek$8.4M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.